Elites swear by it, but so far the data on the race fuel is still lacking
Despite a distinct lack of scientific evidence to support it, Maurten continues to be surrounded with mystique as the official fuelling product of choice for top-flight marathoners like Eliud Kipchoge, Kenenisa Bekele and Geoffrey Kamworor (who will without a doubt be using it on the course at Sunday’s TCS New York City Marathon).
Running a marathon in two hours and change requires an athlete like Kipchoge to take in around 100 grams of carbohydrate per hour, but the diversion of bloodflow from the GI tract to the legs associated with extreme exertion often means the gut cannot absorb the nutrition efficiently, resulting in cramping and the urgent need for a porta-potty. Maurten claims that its use of pectin (the ingredient that makes jams and jellies jell) and sodium alginate combine with the stomach’s natural acid to optimize absorption and minimize GI symptoms. (And the presence or absence of GI symptoms can easily mean the difference between a 2:04 marathon and a 2:11 marathon.)
Last fall we reported on a study of cyclists that found that Maurten did not perform significantly better than a comparable control product or a placebo drink. Hutchinson reports that two new studies have found the same thing–one that appeared in the International Journal of Sport Nutrition and Exercise Metabolism involving nine male runners, in which the control product was identical to the Maurten formulation except for the pectin and sodium alginate (which Maurten claims are the magic ingredients), and another one on cyclists (involving, once again, nine subjects) that appeared in the European Journal of Applied Physiology. Neither study showed any significant advantage to using a product made of pectin and sodium alginate in either performance or symptoms.
Hutchinson concludes: “Taken together, these studies aren’t encouraging for Maurten fans. Whether it’s cycling or running, steady pace or intervals, low volume or high volume of drinking, there’s no apparent advantage to the hydrogel.” Admittedly, the sample sizes were small, and there are other possibly mitigating factors. Still, Hutchinson says he’s still open to persuasion, if and when some meaningful data come to light. In the meantime, that’s one powerful placebo.